Deerfield Management Company L.P. Series C Has $24.45 Million Stake in Savara Inc (NASDAQ:SVRA)

Deerfield Management Company L.P. Series C raised its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 23.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,964,000 shares of the company's stock after acquiring an additional 1,498,223 shares during the quarter. Deerfield Management Company L.P. Series C owned about 4.64% of Savara worth $24,449,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Savara by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after purchasing an additional 365,959 shares during the last quarter. Nantahala Capital Management LLC boosted its holdings in Savara by 45.2% during the fourth quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company's stock valued at $23,103,000 after acquiring an additional 2,344,308 shares during the period. Geode Capital Management LLC boosted its holdings in Savara by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company's stock valued at $8,549,000 after acquiring an additional 57,187 shares during the period. Rosalind Advisors Inc. acquired a new position in shares of Savara during the fourth quarter worth approximately $8,151,000. Finally, Emerald Advisers LLC acquired a new position in shares of Savara during the fourth quarter worth approximately $7,161,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $6.00 price objective on shares of Savara in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Savara presently has an average rating of "Moderate Buy" and an average target price of $8.83.

Savara Trading Up 5.6%

NASDAQ SVRA traded up $0.16 during trading on Monday, reaching $3.02. 1,418,744 shares of the stock traded hands, compared to its average volume of 1,302,198. The stock's 50-day moving average price is $2.90 and its 200 day moving average price is $3.04. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The firm has a market cap of $521.70 million, a price-to-earnings ratio of -7.02 and a beta of 0.44. Savara Inc has a fifty-two week low of $2.26 and a fifty-two week high of $5.11.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million for the quarter. Analysts predict that Savara Inc will post -0.45 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.